Biomol Ther.  2020 Nov;28(6):512-518. 10.4062/biomolther.2020.159.

Inhibition of LPA₅ Activity Provides Long-Term Neuroprotection in Mice with Brain Ischemic Stroke

• Sapkota A
• Park SJ
• Choi JW

• KMID: 2508205
• DOI: http://doi.org/10.4062/biomolther.2020.159

Abstract

Stroke is a leading cause of long-term disability in ischemic survivors who are suffering from motor, cognitive, and memory impairment. Previously, we have reported suppressing LPA₅ activity with its specific antagonist can attenuate acute brain injuries after ischemic stroke. However, it is unclear whether suppressing LPA₅ activity can also attenuate chronic brain injuries after ischemic stroke. Here, we explored whether effects of LPA₅ antagonist, TCLPA5, could persist a longer time after brain ischemic stroke using a mouse model challenged with tMCAO. TCLPA5 was administered to mice every day for 3 days, starting from the time immediately after reperfusion. TCLPA5 administration improved neurological function up to 21 days after tMCAO challenge. It also reduced brain tissue loss and cell apoptosis in mice at 21 days after tMCAO challenge. Such long-term neuroprotection of TCLPA5 was associated with enhanced neurogenesis and angiogenesis in post-ischemic brain, along with upregulated expression levels of vascular endothelial growth factor. Collectively, results of the current study indicates that suppressing LPA₅ activity can provide long-term neuroprotection to mice with brain ischemic stroke.

Keyword

Ischemic stroke; LPA₅; TCLPA5; Long-term neuroprotection; Neurogenesis; Angiogenesis